Investors are often guided by the idea of discovering ‘the next big thing’, even if that means buying ‘story stocks’ without any revenue, let alone profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.
So if this idea of high risk and high reward doesn’t suit, you might be more interested in profitable, growing companies, like Shanghai Shyndec Pharmaceutical (SHSE:600420). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Shanghai Shyndec Pharmaceutical with the means to add long-term value to shareholders.
Check out our latest analysis for Shanghai Shyndec Pharmaceutical
